Patents by Inventor Pankaj Karande
Pankaj Karande has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220096459Abstract: Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.Type: ApplicationFiled: October 12, 2021Publication date: March 31, 2022Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Xiaowei Xu, Shujing Liu, Alain Rook, Pankaj Karande
-
Patent number: 11179385Abstract: Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.Type: GrantFiled: June 30, 2016Date of Patent: November 23, 2021Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Xiaowei Xu, Shujing Liu, Alain Rook, Pankaj Karande
-
Publication number: 20190153035Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.Type: ApplicationFiled: February 1, 2019Publication date: May 23, 2019Inventors: Jeffrey D. Rimer, Pankaj Karande
-
Patent number: 10246489Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.Type: GrantFiled: March 1, 2017Date of Patent: April 2, 2019Assignees: UNIVERSITY OF HOUSTON, RENSSELAER POLYTECHNIC INSTITUTEInventors: Jeffrey D. Rimer, Pankaj Karande
-
Publication number: 20180185350Abstract: Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.Type: ApplicationFiled: June 30, 2016Publication date: July 5, 2018Inventors: Xiaowei Xu, Shujing Liu, Alain Rook, Pankaj Karande
-
Publication number: 20170283459Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.Type: ApplicationFiled: March 1, 2017Publication date: October 5, 2017Inventors: Jeffrey D. Rimer, Pankaj Karande
-
Publication number: 20170216314Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes an active agent, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.Type: ApplicationFiled: April 19, 2017Publication date: August 3, 2017Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Wade A. Hull, Ngoc Truc-Chi Vo
-
Patent number: 9642912Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.Type: GrantFiled: December 22, 2014Date of Patent: May 9, 2017Assignee: Crescita Therapeutics Inc.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Wade A. Hull, Ngoc Truc-Chi Vo
-
Patent number: 9617306Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.Type: GrantFiled: July 9, 2014Date of Patent: April 11, 2017Assignees: UNIVERSITY OF HOUSTON, RENSSELAER POLYTECHNIC INSTITUTEInventors: Jeffrey D. Rimer, Pankaj Karande
-
Patent number: 9308181Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.Type: GrantFiled: March 8, 2013Date of Patent: April 12, 2016Assignee: Nuvo Research Inc.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Tejas Desai, Wade A. Hull
-
Publication number: 20150297723Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.Type: ApplicationFiled: December 22, 2014Publication date: October 22, 2015Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Wade A. Hull, Ngoc Truc-Chi Vo
-
Publication number: 20150099704Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.Type: ApplicationFiled: July 9, 2014Publication date: April 9, 2015Applicants: University of Houston, Rensselaer Polytechnic InstituteInventors: Jeffrey D. Rimer, Pankaj Karande
-
Patent number: 8513304Abstract: It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.Type: GrantFiled: November 19, 2012Date of Patent: August 20, 2013Assignee: Nuvo Research Inc.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Patent number: 8343962Abstract: It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.Type: GrantFiled: August 2, 2010Date of Patent: January 1, 2013Assignee: Nuvo Research Inc.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Publication number: 20110028460Abstract: It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.Type: ApplicationFiled: August 2, 2010Publication date: February 3, 2011Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Patent number: 7795309Abstract: There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation.Type: GrantFiled: March 6, 2007Date of Patent: September 14, 2010Assignee: FQUBED Inc.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Publication number: 20100029769Abstract: There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation.Type: ApplicationFiled: March 6, 2007Publication date: February 4, 2010Applicant: FQUBED INC.Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Publication number: 20090105260Abstract: An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in silico procedure that may be applied iteratively in an attempt to generate molecules showing successively higher performance. Both the irritation potential and the ability of the molecule to enhance penetration are considered in the in silico approach. The invention provides specific molecules that may be used in topical or transdermal formulations to improve the delivery of actives. The structures of compounds of the invention include: Formulas (I), (II), (III), (IV), (V), (IV) and analogs thereof.Type: ApplicationFiled: January 17, 2006Publication date: April 23, 2009Inventors: Samir Mitragotri, Pankaj Karande, Amit K. Jain
-
Publication number: 20080221212Abstract: There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation.Type: ApplicationFiled: March 6, 2007Publication date: September 11, 2008Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri
-
Publication number: 20070269379Abstract: A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a library of chemical penetration enhancer combinations are screened with a high throughput device to identify “hot spots”, particular combinations that show higher chemical penetration enhancement compared to neighboring compositions. The irritation potentials of the hot spot combinations are measured to identify combinations that also show low irritation potential. A active component, such as a drug, is then combined with the combination in a formulation which is tested for the ability of the drug to penetrate into or through skin.Type: ApplicationFiled: July 21, 2004Publication date: November 22, 2007Inventors: Samir Mitragotri, Pankaj Karande, Amit Jain